Oncolytics Biotech announced positive translational data from SITC 2026 showing that its oncolytic virus pelareorep, combined with a checkpoint inhibitor, increases HPV-16-specific T cells and tumor-infiltrating lymphocytes in anal cancer patients, potentially broadening its efficacy across HPV-driven malignancies.